K. von Holt

CYP1A2 and NAT2 phenotyping and 3-aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers.

R. Kinser, J. Oey, K. Rustemeier, 2006, Toxicology and applied pharmacology.

Progression of atherosclerosis in the Apo E-/- model: 12-month exposure to cigarette mainstream smoke combined with high-cholesterol/fat diet.

S. Lebrun, T. Wallerath, R. Schleef, 2009, Atherosclerosis.

Smoking and atherosclerotic cardiovascular disease: part III: functional biomarkers influenced by smoking.

B. Winkelmann, M. Unverdorben, K. von Holt, 2009, Biomarkers in medicine.

Smoking and atherosclerotic cardiovascular disease: part II: role of cigarette smoking in cardiovascular disease development.

B. Winkelmann, M. Unverdorben, K. von Holt, 2009, Biomarkers in medicine.

Smoking and atherosclerotic cardiovascular disease: Part I: atherosclerotic disease process.

B. Winkelmann, M. Unverdorben, K. von Holt, 2009, Biomarkers in medicine.

Biomarkers of exposure and potential harm in adult smokers of 3–7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers

R. Kinser, J. Oey, K. Rustemeier, 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

Karl Broich, Wolfgang Maier, Gabriele Doblhammer, 2016, JAMA neurology.

Smoking and atherosclerotic cardiovascular disease: part IV: genetic markers associated with smoking.

B. Winkelmann, M. Unverdorben, K. von Holt, 2010, Biomarkers in medicine.

Smoking accelerates the progression of hypertension-induced myocardial hypertrophy to heart failure in spontaneously hypertensive rats.

K. Schlüter, K. Meurrens, R. Schleef, 2007, Cardiovascular research.

Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data.

W. Maier, G. Doblhammer, K. Broich, 2016, Journal of Alzheimer's disease : JAD.